Atomwise Overview
- Year Founded
-
2012
- Status
-
Private
- Employees
-
63
- Latest Deal Type
-
Series C
- Latest Deal Amount
-
$45M
- Investors
-
30
Atomwise General Information
Description
Operator of an artificial intelligence-based biotechnology company intended to help invent new potential medicines for disease targets. The company's technology helps in drug hit discovery, binding affinity prediction, and toxicity detection, enabling scientists to discover small molecules for the treatment and investigation of human diseases.
Contact Information
Website
www.atomwise.comCorporate Office
- 250 Sutter Street
- Suite 650
- San Francisco, CA 94108
- United States
Corporate Office
- 250 Sutter Street
- Suite 650
- San Francisco, CA 94108
- United States
Atomwise Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 14. Later Stage VC (Series C) | 18-Feb-2025 | $45M | Completed | Pre-Clinical Trials | ||
| 13. Accelerator/Incubator | Completed | Pre-Clinical Trials | ||||
| 12. Grant | 06-Oct-2020 | Completed | Pre-Clinical Trials | |||
| 11. Later Stage VC (Series B) | 11-Aug-2020 | Completed | Pre-Clinical Trials | |||
| 10. Later Stage VC (Series A) | 02-Jul-2018 | Completed | Pre-Clinical Trials | |||
| 9. Accelerator/Incubator | Completed | Pre-Clinical Trials | ||||
| 8. Accelerator/Incubator | 01-Jan-2016 | Completed | Pre-Clinical Trials | |||
| 7. Seed Round | 05-May-2015 | Completed | Pre-Clinical Trials | |||
| 6. Accelerator/Incubator | 24-Mar-2015 | $120K | $120K | Completed | Pre-Clinical Trials | |
| 5. Angel (individual) | Completed | Startup |
Atomwise Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | ||||||||
| Series A-8 | ||||||||
| Series A-7 | ||||||||
| Series A-6 | ||||||||
| Series A-5 | ||||||||
| Series A-4 | ||||||||
| Series A-3 | ||||||||
| Series A-2 | 159,056 | $0.000010 | 8% | $0.27 | $0.27 | 1x | $0.27 | 0.34% |
| Series A-1 | 9,016,169 | $0.000010 | 8% | $4.99 | $4.99 | 1x | $4.99 | 19.2% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Atomwise Comparisons
Industry
Financing
Details
Atomwise Competitors (28)
One of Atomwise’s 28 competitors is Exscientia, a Formerly VC-backed company based in Oxford, United Kingdom.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Exscientia | Formerly VC-backed | Oxford, United Kingdom | ||||
| Verge Genomics | Venture Capital-Backed | South San Francisco, CA | ||||
| Enterprise Therapeutics | Venture Capital-Backed | Brighton, United Kingdom | ||||
| OrphAI Therapeutics | Venture Capital-Backed | New Haven, CT | ||||
| PlantForm | Venture Capital-Backed | Toronto, Canada |
Atomwise Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Atomwise Patents
Atomwise Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20240417396-A1 | Inhibitors of tyk2 | Pending | 02-Jun-2023 | ||
| US-20240425484-A1 | Inhibitors of tyk2 | Pending | 02-Jun-2023 | ||
| US-20240342167-A1 | Inhibitors of porcine reproductive and respiratory syndrome virus | Pending | 11-Apr-2023 | ||
| EP-4526502-A1 | Systems and method for query-based random access into virtual chemical combinatorial synthesis libraries | Pending | 16-May-2022 | ||
| EP-4515552-A1 | Characterization of interactions between compounds and polymers using pose ensembles | Pending | 29-Apr-2022 | G06N3/045 |
Atomwise Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Atomwise Investors (30)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Gates Foundation | Not-For-Profit Venture Capital | |||
| Cerity Partners Ventures | Corporate Venture Capital | Minority | ||
| Draper Dragon | Venture Capital | Minority | ||
| Sanabil Investments | Growth/Expansion | Minority | ||
| AimTop Ventures | Venture Capital | Minority |
Atomwise Investments (7)
Atomwise’s most recent deal was a Joint Venture with A2i Therapeutics. The deal was made on 01-Nov-2020.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| A2i Therapeutics | 01-Nov-2020 | Joint Venture | Drug Discovery | ||
| Theia Biosciences | 13-Mar-2020 | Joint Venture | Drug Discovery | ||
| Joint Venture (StemoniX and Atomwise) | 03-Dec-2019 | Joint Venture | Drug Discovery | ||
| Atomwise & Atropos (Joint Venture) | 11-Sep-2019 | Joint Venture | Drug Discovery | ||
| Atomwise & OncoStatyx (Joint Venture) | 10-Sep-2019 | Joint Venture | Biotechnology |
Atomwise FAQs
-
When was Atomwise founded?
Atomwise was founded in 2012.
-
Where is Atomwise headquartered?
Atomwise is headquartered in San Francisco, CA.
-
What is the size of Atomwise?
Atomwise has 63 total employees.
-
What industry is Atomwise in?
Atomwise’s primary industry is Drug Discovery.
-
Is Atomwise a private or public company?
Atomwise is a Private company.
-
What is Atomwise’s current revenue?
The current revenue for Atomwise is .
-
How much funding has Atomwise raised over time?
Atomwise has raised $226M.
-
Who are Atomwise’s investors?
Gates Foundation, Cerity Partners Ventures, Draper Dragon, Sanabil Investments, and AimTop Ventures are 5 of 30 investors who have invested in Atomwise.
-
Who are Atomwise’s competitors?
Exscientia, Verge Genomics, Enterprise Therapeutics, OrphAI Therapeutics, and PlantForm are some of the 28 competitors of Atomwise.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
